USPTO serial 76514780
AMERICAN FAMILY PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CRAWFORD, MARY
- Law office
- TMEG LAW OFFICE 102 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with AMERICAN FAMILY PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Suzan Onel
SUZAN ONEL KIRKPATRICK & LOCKHART LLP1800 MASSACHUSETTS AVE NWWASHINGTON, DC 20036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely generic and over-the-counter drugs for the treatment and mitigation of various disease- and health-related conditions, including oral and topical pain relievers and other topical preparations; antibiotics; anti-inflammatory products; cough, cold, and allergy products; ophthalmic products; otic products; and dietary supplements and vitamins | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2005 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 19, 2005 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 21, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2004 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 18, 2004 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jun 21, 2004 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Jun 21, 2004 | PAPER RECEIVED | — | |
| May 24, 2004 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 6, 2003 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2003 | DOCK | ASSIGNED TO EXAMINER | — |